Buckle up

The Trump announcement of a 200% tariff on pharma, deferred for a year so US drugmakers can onshore everything, may be yet another can that he keeps kicking down the road. However, there's likely to be an impact on IDT, at least on the SP, and more worryingly, on its actual US contracts. I'm hoping IDTs path to profitability can withstand this stupid uncertainty. But not counting on it tbh.

Also, this morning's reporting on scrutiny of medicinal cannabis prescribing is unlikely to help. In short, if you're a believer, strap yourself in.